Errors and pitfalls in immunoassays

CPD Bulletin Clinical Biochemistry

Volumn 4, Issue 2, 2002, Pages 45-54

  Sturgeon, Catharine ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Heterophilic antibodies; Immunoassay; Interference

Indexed keywords

ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN; DIGOXIN; HETEROPHILE ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROLACTIN; RHEUMATOID FACTOR; STEROID; TROPONIN; TROPONIN I; VACCINE;

ANALYTICAL ERROR; ASSAY; CARDIOPULMONARY INSUFFICIENCY; CROSS REACTION; DRUG BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART VENTRICLE EXTRASYSTOLE; HOSPITAL LABORATORY; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INFECTION; MEDICAL STAFF; PATIENT CARE; REVIEW;

EID: 0036035514     PISSN: 13678930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Bonini P, Plebani M, Ceriotti F, et al; Errors in laboratory medicine. Clin Chem 2002; 48: 691-8.
2. Wilde C. Subject preparation, sample collection and handling. In: Wild, D, ed. The immunoassay handbook, 2nd ed. Basingstoke: Nature Publishing Group, 2001. Pp 411-423.
3. Young DS. Effects of pre-analytical variables on clinical laboratory tests. American Association for Clinical Chemistry Press, Washington DC, 1997.
4. McSwiney RR, Woodrow DA. Types of error within a clinical laboratory. J Med Lab Technol 1969; 26: 340-6.
5. Lapworth R, Teal TK. Laboratory blunders revisited. Ann Clin Biochem 1994; 31: 78-84.
6. Boone DJ, Steindel SD, Herron R, et al; Transfusion medicine monitoring practices. Arch Pathol Lab Med 1995; 119: 999-1006.
7. Seth J, Sturgeon C, Ellis AR. Annual Reviews of the UK NEQAS for Peptide Hormones. Edinburgh: UK NEQAS 1988-2001.
8. Seth J. Quality assurance. In: Price CP, Newman DJ (eds). Principles and practice of immunoassay, 2nd ed. Basingstoke: MacMillan Press Ltd, 1997. Pp 211-241.
9. Wild D. Immunoassay trouble-shooting guide. In: Wild, D, ed. The immunoassay handbook, 2nd ed. Basingstroke: Nature Publishing Group, 2001. Pp 458-494.
10. Seth J, Sturgeon CM. Pitfalls in immunoassays in endocrinology. AACC Endo 1993; 11: 89-106.
11. Perry B, Chapman RS, McConway MG, et al; Specificity of two-site immunometric assays. Ann Clin Biochem 1991; 28: 83-6.
12. Miller JJ, Valdes R Jr. Methods for calculating cross-reactivity in immunoassays. J Clin Immunoassay 1992; 15: 97-107.
13. Jortani SA, Miller JJ, Helm RA, et al; Suppression of immunoassay results by cross-reactivity. J Clin Ligand Assay 1997; 20: 177-9.
14. Steimer W, Müller C, Eber B, et al; Intoxication due to negative canrenone interference in digoxin drug monitoring. Lancet 1999; 354: 1176-7.
15. Steimer W, Müller C, Eber B. Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem 2002; 48: 507-16.
16. Valdes R, Jortani SA. Unexpected suppression of immunoassay results by cross-reactivity: Now a demonstrated cause for concern. Clin Chem 2002; 48: 405-6.
17. Sturgeon CM. Limitations of assay techniques for tumor markers. In: Diamandis EP, Fritsche H, Schwartz MK, Chan DW, eds. Tumor markers: physiology, pathobiology, technology and clinical applications. Chicago: AACC Press, 2002; p65-81.
18. Wood P. Growth hormone: its measurement and the need for assay harmonization. Ann Clin Biochem 2001; 38: 471-82.
19. Blumsohn A, Al Hadari A. Parathyroid hormone: what are we measuring and does it matter? Ann Clin Biochem 2002; 39: 169-72.
20. Engelbach M, Gorges R, Forst T, et al; Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endoc Metab 2000; 85: 1890-4.
21. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45: 942-56.
22. Kricka LJ. Interferences in immunoassay - still a threat. Clin Chem 2000; 46: 1037-8.
23. Ismail AA, Walker PL. Cawood ML, et al; Interference in immunoassay is an underestimated problem. Ann Clin Biochem 2002; 39: 366-73.
24. Janssen JA, Blankestijn PJ, Docter R, et al; Effects of immunoscintigraphy with monoclonal antibodies in assays of hormones and tumour markers. Br Med J 1989; 298: 1511-3.
25. Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotrophin concentrations. Lancet 2000; 355: 712-5.
26. ABC News Prime Time. Cancer misdiagnosed. AbcNEWS.com, posted on July 26, 2001. [Date retrieved July 8th 2002]; http://more.abcnews.go.com/sections/primetime/2020/primetime_010419_abbott_ feature.html
27. Covinsky M, Laterza O, Pfeifer JD, et al; An IgM γ antibody to Escherichia coli produces false-positive results in multiple immunometric assays. Clin Chem 2000; 46: 1157-61.
28. Remaley AT, Wilding P. Macroenzymes: biochemical characterization, clinical significance, and laboratory detection. Clin Chem 1989; 35: 2261-70.
29. John R, McDowell IFW, Scanlon MG et al; Macroprolactin reactivities in prolactin assays: An issue for clinical laboratories and equipment manufacturers. Clin Chem 2000; 46: 884-5.
30. Plebani M, Mion M, Altinier S, et al; False-positive troponin I attributed to a macrocomplex. Clin Chem 2002; 48: 677-9.
31. Knoblock RJ, Lehman CM, Smith RA, et al; False-positive AxSYM cardiac troponin I results in a 53-year old woman. Arch Pathol Lab Med 2002; 126: 606-9.
32. Kim WJ, Laterza OF, Hock KG, et al; Performance of a revised cardiac troponin method that minimizes interferences from heterophilic antibodies. Clin Chem 2002; 48: 1028-34.
33. Wheeler MJ. Hirsutism and virilization in the female. In: Wild D, ed. The Immunoassay handbook, 1st ed. Hants, United Kingdom: Macmillan Press, 1994: 365-378.
34. Taieb J, Benattar C, Birr AS, et al; Limitations of steroid determination by direct immunoassay. Clin Chem 2002; 48: 583-5.
35. Hill RP, Henson DB, Selby C, et al; Grossly elevated testosterone in three female patients: an assay artefact on the Bayer Immuno-1. Proc ACB Natl Mtg 1998, p.38.
36. Thienpont LM, De Leenheer AP. Efforts by industry toward standardization of serum estradiol-17β measurements. Clin Chem 1998; 44: 671-4.
37. Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery 1998; 42: 913-5.
38. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996; 44: 305-9.
39. Levavi H, Neri A, Bar J, et al; "Hook effect" in complete hydatidiform molar pregnancy: a falsely low level of beta-hCG. Obstet Gynecol 1993; 82S: 720-1.
40. O'Reilly SM, Rustin GJS. Mismanagement of choriocarcinoma due to a false low hCG measurement. Int J Gynecol Cancer 1993; 3: 186-8.
41. Sturgeon CM, Seth J, Ellis AR. Clinical interpretation of laboratory results. Proc UK NEQAS Mtg 1996; 2: 110-5.
42. Marshall WJ, Challand GS. Provision of interpretative comments on biochemical report forms. Ann Clin Biochem 2000; 37: 758-63.
43. Sturgeon CM. Tumor markers in the laboratory: closing the guideline-practice gap. Clin Biochem 2001; 34: 353-9.
44. Waise A, Plebani M. Which surrogate marker can be used to assess the effectiveness of the laboratory and its contribution to clinical outcome? Ann Clin Biochem 2001; 38: 589-95.
45. Bjerner J, Nustad K, Norum LF, et al; Immunometric assay interference: incidence and prevention. Clin Chem 2002; 48: 613-21.